BIO BB Biotech AG

Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis

Edison Investment Research Limited
Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis

20-May-2024 / 11:53 GMT/BST
The issuer is solely responsible for the content of this announcement.


 

London, UK, 20 May 2024

 

Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis

BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opportunities. BION’s performance has picked up in recent months, supported by an improvement in the market environment. Its managers are optimistic about the outlook as declines in interest rates, whenever they eventuate, begin to boost investor sentiment towards the sector, especially the mid- and small-cap companies that BION favours. The fund’s managers also expect ongoing progress by portfolio holdings, as several reach key milestones over the coming months. Unlike most of its peers, BION pays an attractive 5% dividend, calculated on average share price over December each year.  

BION’s shares are currently trading at a small discount to NAV. With performance improving and the sector outlook brightening, this may represent an opportunity for investors to acquire BION shares in this vibrant industry at an especially attractive level.

to view the full report.

All reports published by Edison are available to download free of charge from its website

About Edison: As a content-led investor-relations business, Edison helps companies stand out and meet the right shareholders. Edison’s integrated investor relations solution combines expert analyst content, digital targeting and active investor engagement. This drives liquidity and valuations by building bigger, better informed and more engaged investor audiences globally.

Edison has a proven history of increasing liquidity and valuations for its clients. Edison’s content can be viewed by all investors, anywhere in the world.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Joanne Collins +44 (0)20 3077 5700

Learn more at and connect with Edison on: 

LinkedIn 

X  

YouTube 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1906915  20-May-2024 

fncls.ssp?fn=show_t_gif&application_id=1906915&application_name=news&site_id=research_pool
EN
20/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BB Biotech AG

 PRESS RELEASE

Edison issues report on BB Biotech (BION)

Edison Investment Research Limited Edison issues report on BB Biotech (BION) 26-Jun-2024 / 13:08 GMT/BST The issuer is solely responsible for the content of this announcement.   London, UK, 26 Juni 2024   Edison issues report on BB Biotech (BION) to view the full report. All reports published by Edison are available to download free of charge from its website Edison is authorised and regulated by the . Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities. For more informat...

Pedro Fonseca
  • Pedro Fonseca

BB Biotech - Positive trial news lifts two portfolio holdings

In our last BB Biotech (BION) review note, published in May 2024, we noted that the biotech sector was eagerly awaiting some key milestones, the most important being Alnylam Pharmaceuticals’ late-stage clinical trial of vutrisiran for patients with ATTR cardiomyopathy, a deadly heart disease. Alnylam, which comprised 4.3% of BION’s portfolio at end March 2024, released very positive, statistically significant, Phase III trial results this week. Assuming regulatory clearance, Alnylam expects that...

 PRESS RELEASE

Edison issues review on BB Biotech (BION): A recovering sector with a ...

Edison Investment Research Limited Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis 20-May-2024 / 11:53 GMT/BST The issuer is solely responsible for the content of this announcement.   London, UK, 20 May 2024   Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opport...

Pedro Fonseca
  • Pedro Fonseca

BB Biotech - A recovering sector with a healthy prognosis

BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opportunities. BION’s performance has picked up in recent months, supported by an improvement in the market environment. Its managers are optimistic about the outlook as declines in interest rates, whenever they eventuate, begin to boost investor sentiment towar...

BB Biotech AG: 1 director

A director at BB Biotech AG bought 1,000 shares at 41.450CHF and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch